Corbus Pharmaceuticals (NasdaqCM:CRBP) FY Conference February 25, 2026 03:20 PM ET Speaker0Afternoon, everyone, welcome back to Oppenheimer's 36th Annual Healthcare Conference. I'm Jeff Jones, one of the biotech analysts on the team here, I'm delighted to welcome Yuval Cohen, CEO of Corbus Pharmaceuticals. Well, I can talk. Good afternoon, Yuval. How are you?Speaker1Hello, Jeff. How are you?Speaker0Good. Thank you for joining us today. It's, you know, a great way to kick off an exciting 2026 for you guys.Sp ...

Connecting Innovation to Purpose Corporate Presentation February 25, 2026 www.corbuspharma.com @corbuspharma NASDAQ: CRBP 1 Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market op ...

Core Insights - Corbus Pharmaceuticals Holdings Inc. is set to present a corporate overview and engage in investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026 [1][2]. Company Overview - Corbus Pharmaceuticals is a clinical-stage company focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [2]. - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells to deliver a cytotoxic payload [2]. - CRB-601: An anti-integrin monoclonal antibody that inhibits the activation of TGFβ on cancer cells [2]. - CRB-913: A highly peripherally restricted CB1 inverse agonist designed for obesity treatment [2]. - Corbus is headquartered in Norwood, Massachusetts [2].

Core Insights - Corbus Pharmaceuticals is presenting at the 44th Annual JPMorgan Healthcare Conference, focusing on key assets and upcoming milestones [1][2] Group 1: Upcoming Milestones - The company plans to highlight important milestones for its ADC (Antibody-Drug Conjugate) this year [2] - A significant focus will be on the maturing data for CRB-701, particularly regarding its second-line monotherapy in head and neck cancer [3] Group 2: Data Presentation - Updated data on CRB-701 was presented at ESMO, indicating an increase in patient numbers and longer duration of response [3] - The company aims to present further maturing data at a large oncology conference later this year, emphasizing the duration of response for patients [4]

Summary of Corbus Pharmaceuticals FY Conference Call Company Overview - **Company**: Corbus Pharmaceuticals (NasdaqCM:CRBP) - **Date of Conference**: January 15, 2026 - **Key Speaker**: CEO Yuval Cohen Key Points on Drug Development and Pipeline CRB-701 (Oncology) - **Indications**: Focus on second-line monotherapy for head and neck cancer and cervical cancer - **Data Presentation**: Updated data presented at ESMO, with emphasis on the duration of response for patients in second-line head and neck cancer [3] - **FDA Discussions**: Ongoing discussions with the FDA regarding the registrational pathway for CRB-701 in both head and neck and cervical cancers, with expectations of clarity on the regulatory process [4][5] - **Durability of Response**: Key question remains on how durable the response is for patients treated with CRB-701 in both indications [3][4] - **First-Line Treatment**: Emerging data from a study combining CRB-701 with Keytruda in first-line head and neck cancer, with expectations for data maturation later in the year [5][6] CRB-913 (Obesity) - **Mechanism**: A once-a-day oral small molecule CB1 inverse agonist, with a focus on obesity treatment [8] - **Comparison with Monlunabant**: CRB-913 is more restricted in the brain compared to Monlunabant, leading to potentially fewer adverse effects [10][11] - **Safety Profile**: Initial phase 1A data shows a mild profile of gastrointestinal adverse events, significantly better than Monlunabant, which had higher GI toxicity [15][19] - **Neuropsychiatric Events**: No clinical events of neuropsychiatric adverse events reported in CRB-913 trials, contrasting with Monlunabant's high incidence [18][19] - **Weight Loss Results**: Significant weight loss observed in participants, with an average of nearly 3% weight loss after one week of dosing [20][21] - **Efficacy Comparison**: CRB-913 shows potential to be more potent than Rimonabant and Monlunabant, with a promising safety profile [25][27] Financial Position - **Cash Reserves**: Corbus Pharmaceuticals reported having $172 million in cash, providing a runway for both oncology and obesity programs into 2028 [44] Additional Insights - **Regulatory Environment**: The current FDA environment is perceived as less welcoming to single-arm accelerated approval studies compared to previous years [4] - **Market Positioning**: The company aims to position CRB-701 in a competitive landscape dominated by EGFR combinations in first-line head and neck cancer [6] - **Future Milestones**: Anticipated data releases and regulatory updates for both CRB-701 and CRB-913 throughout 2026 [33] Conclusion Corbus Pharmaceuticals is actively advancing its oncology and obesity drug pipelines, with significant upcoming milestones and a strong financial position to support its initiatives. The focus on safety and efficacy in both CRB-701 and CRB-913 highlights the company's commitment to addressing unmet medical needs in these therapeutic areas.

Group 1 - Corbus Pharmaceuticals Holdings Inc. is a clinical-stage company focused on oncology and obesity, with a commitment to innovative scientific approaches to serious illnesses [2] - The company will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco, CA [1] - Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation; and CRB-913, a CB1 inverse agonist for obesity treatment [2]

Core Insights - Several small-cap biotech and healthcare companies experienced notable gains in after-hours trading, driven by recent corporate updates and clinical milestones Company Updates - Inspira Technologies Oxy B.H.N. Ltd. (IINN) rose 5.88% to $1.08 following a recent definitive agreement for a registered direct offering of its ordinary shares and a Standby Equity Purchase Agreement with YA II PN, Ltd. [2] - Galectin Therapeutics Inc. (GALT) increased by 1.79% to close at $6.27, despite no new corporate developments reported [3] - MediciNova, Inc. (MNOV) advanced 4.83% to $1.52 after successfully completing patient enrollment in its Phase 2 OXTOX study, evaluating MN-166 for chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients [4] - Marker Therapeutics, Inc. (MRKR) gained 5.56% to $1.33 without any new company-specific announcements [5] - Sharps Technology, Inc. (STSS) climbed nearly 4% to $2.09, also without fresh updates [6] - DiaMedica Therapeutics Inc. (DMAC) rose 2.89% to $8.55 after a productive pre-IND meeting with the FDA regarding its planned study of DM199 in preeclampsia [6] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) edged higher by 1.36% to $8.21, following the completion of its Phase 1a study of CRB-913 and initiation of the Phase 1b CANYON-1 trial [7] - ProMIS Neurosciences, Inc. (PMN) added 0.83% to $8.49, recovering slightly after a decline earlier in the day, with the completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for Alzheimer's disease [8]

Core Viewpoint - Corbus Pharmaceuticals held an investor webinar to discuss recent results related to their single-ascending and multiple-ascending dose studies [2]. Group 1: Company Overview - Yuval Cohen, the CEO and Director of Corbus Pharmaceuticals, led the webinar and expressed gratitude for the participants' attendance [2]. - The company is focusing on forward-looking statements regarding their research and development efforts [2]. Group 2: Expert Involvement - Dr. Sarah Barenbaum, an Assistant Professor of Clinical Medicine at Weill Cornell Medical College, joined the discussion to provide insights on the data announced [3]. - Dr. Barenbaum specializes in obesity and weight-related medical complications, indicating the company's focus on relevant medical fields [3].

Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) Update Summary Company Overview - **Company**: Corbus Pharmaceuticals Holdings - **Event**: Investor Webinar held on December 11, 2025 Key Points Industry and Product Focus - The discussion centers around the development of **CRB-913**, a novel **CB1 inverse agonist** aimed at treating obesity and weight-related medical complications [1][2][5] - Comparison is made with **Monlunabant**, another CB1 inverse agonist, highlighting differences in brain exclusion and safety profiles [5][6][11] Clinical Study Insights - **Study Design**: The **Single Ascending Dose (SAD)** and **Multiple Ascending Dose (MAD)** studies involved healthy volunteers and participants with obesity, focusing on safety and pharmacokinetics (PK) [6][7][8] - **Dosing**: CRB-913 was administered at doses up to **600 mg**, significantly higher than effective doses of Monlunabant [7] - **Safety Profile**: CRB-913 exhibited a favorable safety profile with minimal gastrointestinal (GI) adverse events, contrasting sharply with Monlunabant, which had a high incidence of GI issues [9][10][11] Efficacy and Weight Loss Results - Participants in the obesity cohort (average BMI of **36**) experienced weight loss of **2.9%** over **14 days**, with no weight loss in the placebo group [13][52] - Weight loss was not associated with GI adverse events, indicating a unique mechanism of action for CRB-913 [22][39] - The drug demonstrated a long half-life, contributing to sustained weight loss effects beyond the dosing period [45][46] Neuropsychiatric Safety - CRB-913 showed no significant neuropsychiatric adverse events, with validated questionnaires indicating no cases of suicidality or depression among participants [11][12][25] - Mild anxiety was reported in a few cases, but these did not trigger any significant concerns [26][27] Future Directions - Corbus Pharmaceuticals plans to initiate **CANYON-1**, a Phase 1b study focusing on safety and tolerability, with a titration approach to dosing [19][20] - The company aims to learn from Monlunabant's experiences to improve patient outcomes and safety [19][20] Market Context and Need - There is a recognized need for diverse treatment options in obesity management, as many patients do not respond adequately to existing therapies, particularly GLP-1 agonists [33][34][35] - The potential for combination therapies targeting different pathways in obesity treatment is emphasized [34][35] Conclusion - The data presented indicates that CRB-913 has a promising profile as a treatment for obesity, with early indications of efficacy and a favorable safety profile compared to existing therapies [22][39][56] - Further studies are necessary to confirm these findings and establish the drug's role in clinical practice [56][58]

Core Insights - Corbus Pharmaceuticals has completed the Phase 1a study of CRB-913 and initiated a Phase 1b study, with results expected in summer 2026 [1][8] Study Overview - The Phase 1a study included a double-blinded placebo-controlled design, assessing safety, tolerability, and pharmacokinetics of CRB-913 with a maximum dose of 600 mg/day [2] - The study involved 64 participants in the single ascending dose (SAD) portion and 48 participants in the multiple ascending dose (MAD) portion [2] Safety and Tolerability - No serious treatment-emergent adverse events were reported, and CRB-913 showed no gastrointestinal intolerability [3] - Neuropsychiatric assessments indicated stability with no reported cases of suicidality, depression, or insomnia [4][5] Efficacy Results - In the obese MAD cohort, participants treated with CRB-913 experienced a placebo-adjusted mean weight loss of 2.9% by Day 14, with individual weight loss ranging from 1.3% to 4.3% [6][8] - Participants reported a reduction in food-related thoughts and cravings, indicating potential efficacy in weight management [6] Future Developments - The Phase 1b CANYON-1 study will involve 240 obese, non-diabetic participants and will assess three dosing cohorts of CRB-913 [11] - The study design includes a dose titration regimen starting at 20 mg/day [11] About CRB-913 - CRB-913 is a peripherally restricted CB1 inverse agonist designed to minimize brain penetration, potentially reducing neuropsychiatric risks associated with earlier drugs in this class [12]